This is a list of adverse effects of the anti-cancer drug nilotinib, sorted by frequency of occurrence.
Very common
Very common (>10% incidence) adverse effects include:
- Headache
- Nausea
- Hypophosphataemia
- Hyperbilirubinaemia
- Alanine aminotransferase (ALT) increased
- Aspartate aminotransferase increased
- Lipase increased
- Rash
- Itchiness
- Hair loss
- Dry skin
- Muscle aches
- Fatigue
Common
Common (1–10% incidence) adverse effects include:
- Constipation
- Diarrhoea
- Vomiting
- Upper abdominal pain
- Indigestion
- Joint pain
- Muscle spasms
- Pain in extremities
- Asthenia
- Peripheral oedema
- Folliculitis
- Upper respiratory tract infection (including pharyngitis, nasopharyngitis, rhinitis)
- Skin papilloma
- Eosinophilia
- Lymphopenia
- Insomnia
- Anxiety
- Depression
- Diabetes mellitus
- Hypercholesterolaemia
- Hyperlipidaemia
- Hypertriglyceridaemia
- Hyperglycaemia
- Loss of appetite
- Dizziness
- Hypoaesthesia
- Peripheral neuropathy
- Eye pruritus
- Conjunctivitis
- Dry eye (including xerophthalmia)
- Vertigo
- Flushing
- Hypertension
- Angina pectoris
- Arrhythmia (including atrioventricular block, tachycardia, atrial fibrillation, ventricular extrasystoles, bradycardia)
- QT interval prolonged
- Palpitations
- Cough
- Dyspnoea
- Abdominal distension
- Abdominal discomfort
- Taste changes
- Flatulence
- Abnormal liver function
- Bone pain
- Back pain
- Erythema
- Hyperhidrosis
- Contusion
- Acne
- Dermatitis (including allergic, exfoliative and acneiform)
- Night sweats
- Fever without an infectious cause
- Chest pain (including non-cardiac chest pain)
- Chest discomfort
- Decreased haemoglobin
- Increased blood amylase
- Increased blood alkaline phosphatase
- Gamma-glutamyltransferase increased
- Weight increased
- Increased blood insulin
- Increased lipoprotein (including very low density and high density)
Uncommon
Uncommon (0.1–1% incidence) adverse effects include:
- Arteriosclerosis
- Bone marrow suppression
- Both increases and decreases of potassium levels
- Body temperature change sensation (both hot and cold)
- Chills
- Cognitive deficits
- Conjunctival bleeding and redness
- Cyanosis
- Dental sensitivity to pain
- Bleeding into the lungs
- Increased blood cholesterol and lipid levels
- Dystonia
- Erectile dysfunction
- Eyelid swelling
- Flank pain
- Gastritis
- Gout
- Decreased calcium levels
- Jaundice
- Malaise
- Migraine
- Muscle pain and weakness
- Pancreatitis
- Paraesthesia
- Peripheral arterial occlusive disease
- Photopsia
- Pleural effusion
- Skin eruptions
- Skin pain
- Decreased globulins
References
- "Complete Nilotinib information from Drugs.com". Drugs.com. Retrieved 25 January 2014.
- "Tasigna : EPAR - Product Information" (PDF). European Medicines Agency. Novartis Europharm Ltd. 18 October 2013. Retrieved 25 January 2014.
- "Tasigna 150mg Hard Capsules - Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Novartis Pharmaceuticals UK Ltd. 9 September 2013. Retrieved 25 January 2014.
- "TASIGNA® nilotinib" (PDF). TGA eBusiness Services. 21 October 2013. Retrieved 25 January 2014.
- "Tasigna (nilotinib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 25 January 2014.
- Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.
- ^ Chan, J; Shah, P; Moguel-Cobos, G (2019). "Nilotinib-Induced Dystonia and Cognitive Deficits in a Neurologically Normal Patient with Chronic Myeloid Leukemia". Case Reports in Neurological Medicine. 2019: 3679319. doi:10.1155/2019/3679319. PMC 6875312. PMID 31781436.
- Donatelli, C., D. Chongnarungsin, and R. Ashton. (Oct 2014). "Acute respiratory failure from nilotinib-associated diffuse alveolar hemorrhage". Leuk Lymphoma. 55 (10): 2408–9. doi:10.3109/10428194.2014.887714. PMID 24467220. S2CID 43118790.
{{cite journal}}: CS1 maint: multiple names: authors list (link)